BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 26735353)

  • 1. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.
    Trisolini E; Armellini E; Paganotti A; Veggiani C; Bozzola C; Frattini M; Pizio C; Mancuso G; Andorno S; Boldorini R
    Pathology; 2017 Jun; 49(4):379-386. PubMed ID: 28450086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
    Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
    J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.
    Buscail L; Bournet B; Cordelier P
    Nat Rev Gastroenterol Hepatol; 2020 Mar; 17(3):153-168. PubMed ID: 32005945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [KRAS mutation assay on EUS-FNA specimens from pacients with pancreatic mass].
    Bunganič B; Hálková T; Benešová L; Belšánová B; Laclav M; Hrůzová M; Traboulsi E; Frič P; Suchánek Š; Minárik M; Zavoral M
    Cas Lek Cesk; 2016; 155(1):48-51. PubMed ID: 26898792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcinoma.
    Park JK; Lee YJ; Lee JK; Lee KT; Choi YL; Lee KH
    Oncotarget; 2017 Jan; 8(2):3519-3527. PubMed ID: 27974679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration.
    Matsumoto K; Kato H; Nouso K; Ako S; Kinugasa H; Horiguchi S; Saragai Y; Takada S; Yabe S; Muro S; Uchida D; Tomoda T; Okada H
    Dig Dis Sci; 2020 Oct; 65(10):2907-2913. PubMed ID: 31897893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
    Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
    Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration.
    Hosoda W; Takagi T; Mizuno N; Shimizu Y; Sano T; Yamao K; Yatabe Y
    Pathol Int; 2010 May; 60(5):358-64. PubMed ID: 20518885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts.
    Nikiforova MN; Khalid A; Fasanella KE; McGrath KM; Brand RE; Chennat JS; Slivka A; Zeh HJ; Zureikat AH; Krasinskas AM; Ohori NP; Schoedel KE; Navina S; Mantha GS; Pai RK; Singhi AD
    Mod Pathol; 2013 Nov; 26(11):1478-87. PubMed ID: 23743931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.
    Maluf-Filho F; Kumar A; Gerhardt R; Kubrusly M; Sakai P; Hondo F; Matuguma SE; Artifon E; Monteiro da Cunha JE; César Machado MC; Ishioka S; Forero E
    J Clin Gastroenterol; 2007; 41(10):906-10. PubMed ID: 18090159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation.
    Mansour Y; Boubaddi M; Odion T; Marty M; Belleannée G; Berger A; Subtil C; Laurent C; Dabernat S; Amintas S
    Cancer Cytopathol; 2024 May; 132(5):274-284. PubMed ID: 38308613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.
    Kwon MJ; Jeon JY; Park HR; Nam ES; Cho SJ; Shin HS; Kwon JH; Kim JS; Han B; Kim DH; Choi YL
    Pancreas; 2015 Apr; 44(3):484-92. PubMed ID: 25513781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FNA smears of pancreatic ductal adenocarcinoma are superior to formalin-fixed paraffin-embedded tissue as a source of DNA: Comparison of targeted KRAS amplification and genotyping in matched preresection and postresection samples.
    Hartley CP; Mahajan AM; Selvaggi SM; Rehrauer WM
    Cancer Cytopathol; 2017 Nov; 125(11):838-847. PubMed ID: 29024530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.